Exploring systemic options for advanced hepatocellular carcinoma

 Paperback
Print on Demand | Lieferzeit:3-5 Tage I

71,90 €*

Alle Preise inkl. MwSt. | zzgl. Versand
ISBN-13:
9783659430138
Einband:
Paperback
Seiten:
168
Autor:
Omar Abdel-Rahman
Gewicht:
267 g
Format:
220x150x10 mm
Sprache:
Englisch
Beschreibung:
The only approved systemic therapy for patients with advanced hepatocellular carcinoma (HCC) till now is sorafenib. A preliminary study suggested that capecitabine, an oral fluoropyrimidine, may be effective in advanced HCC. We have tested this hypothesis in this phase 2 study. In this single-center, phase 2, open-label trial, we randomly assigned 52 patients with advanced HCC who had not received previous systemic treatment to receive either sorafenib (at a dose of 400 mg twice daily) or capecitabine (1,000 mg/m2 twice daily) (day 1-day 14). Primary outcome was progression-free survival. Secondary outcomes included the overall survival and safety.

Kunden Rezensionen

Zu diesem Artikel ist noch keine Rezension vorhanden.
Helfen sie anderen Besuchern und verfassen Sie selbst eine Rezension.